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Abstract: The authors have previously designed, developed, and characterized a novel 
microencapsulated formulation as a platform for the targeted delivery of therapeutics in an 
animal model of type 2 diabetes, using the drug probucol (PB). The aim of this study was to 
optimize PB microcapsules by incorporating the bile acid deoxycholic acid (DCA), which has 
good permeation-enhancing properties, and to examine its effect on microcapsules’ morphol-
ogy, rheology, structural and surface characteristics, and excipients’ chemical and thermal 
compatibilities. Microencapsulation was carried out using a BÜCHI-based microencapsulating 
system established in the authors’ laboratory. Using the polymer sodium alginate (SA), two 
microencapsulated formulations were prepared: PB-SA (control) and PB-DCA-SA (test) at a 
constant ratio (1:30 and 1:3:30, respectively). Complete characterization of the microcapsules 
was carried out. The incorporation of DCA resulted in better structural and surface characteris-
tics, uniform morphology, and stable chemical and thermal profiles, while size and rheological 
parameters remained similar to control. In addition, PB-DCA-SA microcapsules showed good 
excipients’ compatibilities, which were supported by data from differential scanning calorimetry, 
Fourier transform infrared spectroscopy, scanning electron microscopy, and energy dispersive 
X-ray studies, suggesting microcapsule stability. Hence, PB-DCA-SA microcapsules have 
good rheological and compatibility characteristics and may be suitable for the oral delivery of 
PB in type 2 diabetes.
Keywords: artificial cell microencapsulation, diabetes, bile acids, probucol, antioxidant, anti-
inflammatory, BÜCHI B390
Introduction
Diabetes mellitus is a metabolic disorder classified as type 1 diabetes or type 2 diabetes 
(T2D).1,2 Type 1 diabetes is an autoimmune disease marked by the destruction of 
β-cells of the pancreas, resulting in a partial or complete lack of insulin production and 
the inability of the body to control glucose levels.3 T2D develops due to genetic and 
environmental factors that lead to tissue desensitization to insulin.4 Current therapies 
are aimed at resolving the persistent hyperglycemia by increasing available insulin or 
improving tissue sensitivity.5,6 However, damage of pancreatic β-cells and the build-up 
of free radicals and toxins, together with persistent inflammation, remain detrimental 
in diabetes treatment and long-term prognosis.7
There is growing evidence for the use of antioxidants as adjuncts in the treatment 
of T2D.8–10 Probucol (PB) is a drug that was initially developed to treat hyperlipidemia, 
but its strong anti-inflammatory and antioxidant properties have made it a potential 
therapeutic agent in the treatment of T2D.11,12 In addition, PB has shown a protective 
effect on pancreatic β-cells.13,14 It is highly lipophilic and accumulates extensively 
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in adipose tissues.15 PB has very low bioavailability but its 
pharmacokinetic and pharmacodynamic parameters show 
great variation between individuals.16,17 Thus, the low and 
variable oral bioavailability and the non-linear distribu-
tion and clearance of PB contribute to the variability in its 
efficacy as well as its side effects.9,18 So, despite the huge 
potential of PB in T2D, its variable and poor kinetics remain 
major obstacles to its clinical use.9 Designing a novel and 
stable formulation with good rheological parameters and 
permeation-enhancing properties is anticipated to overcome 
these obstacles. This can be achieved by incorporating a 
bile acid with permeation-enhancing characteristics, such as 
deoxycholic acid (DCA),19 in a novel delivery system using 
artificial cell microencapsulation technology.
Artificial cell microencapsulation is commonly used to 
improve the delivery of lipophilic drugs that exhibit low 
bioavailability and poor dissolution and absorption kinetics.20 
It encapsulates a drug using a biodegradable polymer such as 
sodium alginate (SA), which protects the drug and provides a 
pH-sensitive targeted delivery after oral administration. The 
choice of polymer has a significant impact on the formula-
tion properties and efficacy as well as on the drug’s chemical 
and thermal characteristics.21 Previous work by the authors’ 
research group19,20,22–27 on the formulation of the antidiabetic 
drug gliclazide, alone or combined with bile acids (in vitro 
and in vivo), and their recently designed and formulated 
microcapsule platform have demonstrated improved tar-
geted delivery when using an SA-based formulation. Thus, 
this study aimed to examine the potential of these newly 
developed microcapsules in producing a novel and stable 
PB formulation suitable for oral delivery in T2D through 
the incorporation of the bile acid DCA.
Materials and methods
Materials
PB (98%), low-viscosity SA (99%), and DCA (98%) were 
purchased from Sigma-Aldrich Co., (St Louis, MO, USA). 




O, 98%) was obtained 
from Scharlab S.L (Sentmenat, Spain). All solvents and 
reagents were supplied by Merck KGaA (Darmstadt, Germany) 
and were of high-performance liquid chromatography grade 
and used without further purification.
Drug preparation
Stock suspensions of PB (20 mg/mL) and DCA (1 mg/mL) 
were prepared, as previously described,28 by adding the 
powder to 10% ultrapure water-soluble gel. The CaCl
2
 
stock solution (2%) was prepared by adding CaCl
2
 powder 
to high-performance liquid chromatography water. All 
preparations were mixed thoroughly at room temperature, for 
4 hours, stored in the refrigerator, and used within 48 hours 
of preparation.
Preparation of microcapsules
Microcapsules of PB-loaded low-viscosity SA were pre-
pared using a BÜCHI-based microencapsulating system 
(BÜCHI Labortechnik AG, Flawil, Switzerland). Polymer 
solutions containing SA and PB with or without DCA were 
made up to a final concentration (of PB-DCA-SA) in a ratio 
of 1:3:30, respectively. This ratio was based on the authors’ 
published work29 and was found to exhibit maximum con-
sistency and best morphology. Parameters used include: 
a frequency range of 1,000–1,500 Hz, air flow of 4 mL/
minute, and a constant air pressure of 300 mbar. Microcap-
sules were collected from the microencapsulating system, 
and for each formulation, three independent batches were 
prepared and tested separately (n=3). All microcapsules 
(PB-SA-loaded and PB-DCA-SA-loaded) were prepared and 
treated in the exact same way. Microcapsules were dried by 
using stability chambers (ACS Environmental and Climatic 
Test Chamber; Angelantoni Test Technologies Srl, Massa 
Martana, Italy).
characterization of loaded microcapsules: 
morphology, size analysis, and chemical 
characterization of microcapsules
All microcapsules were freshly made, stored in the refrigera-
tor, and used within 48 hours of preparation. The appearance 
and size of microcapsules were examined using light micros-
copy followed by scanning electron microscopy (SEM) and 
energy dispersive X-ray spectrometry (EDS). The particle 
size distribution and mean particle size diameter were cal-
culated using the software provided.
Optical microscopy
Morphological characteristics and particle size analysis 
were determined with optical microscopy utilizing a YS2-H 
microscope (Nikon Corporation, Tokyo Japan) mounted with 
an FMA050 fixed calibrated microscope adaptor (ToupTek 
Photonics Co., Ltd., Hangzhou, People’s Republic of China). 
Sample analysis was carried out in triplicate as previously 
described.28 Briefly, predetermined quantities (ten microcap-
sules from each formulation) of freshly prepared microcap-
sules were loaded onto a glass slide mounted to a calibrated 
scale. Optical microscopy software (ToupTek; ProSciTech, 
Australia) capable of particle size analysis, microcapsule 
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characterization, and morphological assessments was utilized 
to determine basic characteristics of the microcapsules to 
complement the SEM studies.
seM and eDs
The surface morphology of the microcapsules was examined 
using SEM (Neon 40 EsB; Carl Zeiss Meditec AG, Jena, 
Germany) with 0.8 nm calibrated resolution. The chemical 
characterization of the microcapsules was examined using 
EDS (INCA® X-Act; Oxford Instruments plc, Abingdon, 
UK). The samples were mounted on a glass stub with 
double-sided adhesive tape and coated under vacuum with 
platinum (5 nm) in an argon atmosphere prior to examina-
tion. Micrographs at different magnifications were recorded 
to study the morphological and surface characteristics of the 
microcapsules.
Determination of dispersing media viscosity
Viscosities of both preparations (PB-SA-loaded and PB-
DCA-SA-loaded microcapsules) were measured for freshly 
prepared mixtures, using 15 mL aliquots (n=3) at room 
temperature using a viscometer (Bohlin Visco 88; Malvern 
Instruments, Malvern, UK).
Differential scanning calorimetric (Dsc) analysis
DSC thermograms of PB, DCA, and low-viscosity SA pow-
ders, their physical mixture, and their microencapsulated 
formulations were carried out in a DSC instrument (DSC 
8000; PerkinElmer Inc., Waltham, MA, USA) as previously 
described.30 Briefly, 5 mg samples were placed in sealed 
aluminum pans and heated at 20°C/minute under a nitrogen 
atmosphere (flow rate 30 mL/minute) in the 35°C–240°C 
range. An empty aluminum pan was used as a reference. 
The equipment was calibrated for baseline and temperature 
with zinc metal.
Fourier transform infrared (FTir) spectral studies
FTIR spectra of pure components, their physical mixture, 
and the microcapsules were recorded using an attenuated 
total reflectance FTIR spectrometer (Spectrum TWO™; 
PerkinElmer), and infrared measurements were performed 
in transmission in the scanning range of 450–4,000 cm-1 at 
room temperature.
statistical analysis
Values are expressed as mean ± standard deviation. Size 
measurements were assessed using Student’s t-test. Statisti-
cal analysis was done using a two-way analysis of variance, 
with Tukey’s honest significant difference post hoc compari-
son of means used only when the associated main effect or 
interaction was statistically significant. The best fit model 
was derived using Prism® version 6.0 software (GraphPad 
Software, Inc., La Jolla, CA, USA). Statistical significance 
was set at P0.05.
Results and discussion
Morphology, size analysis, and chemical 
characterization of microcapsules
Microcapsules were obtained using a low-viscosity SA 
polymer, PB, and DCA at a constant ratio of 30:1:3, respec-
tively. Using the microencapsulation system, all microcap-
sules were of similar size. The mean diameters ranged from 
2,000–2,300 μm for all batches of both formulations, which 
suggest they may also be considered as macrocapsules. The 
mean particle size was not significantly affected by the pres-
ence of DCA.
Optical microscopy
Microcapsules obtained from optical microscopy revealed 
uniform consistency and spherical shaped microcapsules 
with similar sizes, as determined via a calibrated scale 
mounted onto a glass slide. Ten microcapsules were selected 
for particle size and morphological analysis from each 
formulation and repeated in triplicate. The mean diameter 
of PB microcapsules (average ± standard deviation) was 
2,150±150 μm, while that of PB-DCA-SA microcapsules was 
2,350±90 μm. Figure 1A shows PB-SA microcapsules and 
Figure 1B shows PB-DCA-SA microcapsules. L1 shows the 
microcapsule membrane thickness, L2 shows the horizontal 
diameter, and L3 shows the vertical diameter. The calibrated 
optical microscopy size analysis revealed very similar sizes 
and morphological characteristics between both microen-
capsulated formulations, and thus the addition of DCA to 
PB microcapsules did not adversely affect the size, shape, 
or characteristics of the microcapsules.
seM
The results from optical microscopy were further comple-
mented by SEM data of a PB-SA microcapsule (Figure 2) and 
PB-DCA-SA microcapsule (Figure 3), which were randomly 
selected from a few batches. SEM results showed consistently 
uniform microcapsules with well-defined spherical shapes, 
and reflect the optical microscopy findings. The microcap-
sule size difference between different formulations was not 
significant, meaning the addition of DCA did not adversely 
affect the size, morphology, uniformity, and sphericity of 






Figure 1 Optical microscopy of PB-sa and PB-Dca-sa microcapsules.
Notes: (A) PB-sa microcapsules. (B) PB-Dca-sa microcapsules.




Figure 2 scanning electron micrographs of a PB-sa microcapsule.
Notes: (A) 200 μm scale. (B) surface morphology at 10 μm scale. (C) 200 nm scale. (D) 1 μm scale.
Abbreviations: PB, probucol; sa, sodium alginate.
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the microcapsules. The microcapsule surfaces were rough 
but consistent from one microcapsule to another. For PB-SA 
microcapsules, small crystals were distributed throughout 
the microcapsule surface (Figure 2C), either as large clumps 
or smaller groups. These crystals coating the microcapsule 
surface were believed to be PB, but this was not observed 
with the PB-DCA-SA microcapsules (Figure 3). They were 
confirmed to be PB by EDS studies (Figures 4 and 5).
eDs
The surface composition of both PB-SA and PB-DCA-SA 
microcapsules were analyzed through EDS. This form of 
analysis allows identification of surface elemental composi-
tion, as each element from the periodic table displays unique 
EDS patterns.31 Surface crystal depositions and microcapsule 
surface composition and characteristics were also evident 
from this analysis. Figures 4 and 5 show an example of both 
PB-SA and PB-DCA-SA microcapsule surfaces with the cor-
responding surface sites where EDS analysis was conducted. 
Figures 4A–B and 5A–B show PB deposition on the surface 
of the microcapsules, while Figures 4C–D and 5C–D show 
general surface characteristics of the microcapsules.
EDS examination of crystal depositions on the microcap-
sule surfaces (Figures 4 and 5) showed high levels of sulfur 
atoms, evident as small crystals on the surface of PB-SA 
(Figures 4A and B) and, to a lesser extent, of PB-DCA-SA 
(Figures 5A and B) microcapsules. The crystals were from 
PB deposition as no other excipient contains sulfur.32–35 The 
SEM (Figures 2 and 3) and EDS (Figures 4 and 5) results 
suggest that PB preferentially coats the microcapsule surface, 
forming scattered clumps of drug agglomerates distributed 
around the microcapsule surface. Interestingly, and in line 
with the authors’ previous studies, DCA seems to reduce 
the extent of PB surface deposition and the overall poros-
ity, thus providing membrane reinforcement and improving 
microcapsule integrity.36
Viscosity of the microencapsulated formulation
Table 1 shows the viscosity, shear rate, shear stress, and 
torque for both microencapsulated formulations under various 
A B
C D
Figure 3 scanning electron micrographs of a PB-Dca-sa microcapsule.
Notes: (A) 100 μm scale. (B–D) surface morphology from different angles at 10 μm scale.
Abbreviations: Dca, deoxycholic acid; PB, probucol; sa, sodium alginate.
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Figure 4 energy dispersive X-ray spectra of PB-sa microcapsules.
Notes: (A and B) PB deposition (indicated by 1) with corresponding analysis. (C and D) surface composition (indicated by 2) with corresponding analysis.
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Figure 5 energy dispersive X-ray spectra of PB-Dca-sa microcapsules.
Notes: (A and B) PB deposition (indicated by 1) with corresponding analysis. (C and D) surface composition (indicated by 2) with corresponding analysis.
Abbreviations: Dca, deoxycholic acid; PB, probucol; sa, sodium alginate.
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speeds (20, 35, 61, 107, 187, 327, 572, and 1,000 rpm). The 
PB-SA formulation was more viscous, and both formulations 
behaved as non-Newtonian fluids under shear stress.37,38 Both 
formulations behaved as thixotropic fluids under increasing 
stress, as evidenced by parallel reductions in their apparent 
viscosity.39,40 Increasing speeds resulted in the solutions 
forming rapid circular motions away from the origin of the 
centripetal force, suggesting that both formulations also 
behaved in a non-Weissenberg fashion.41,42
Dsc
DSC is commonly used for the thermal characterization 
of various materials.43,44 In PB microencapsulation, DSC 
measures how physical properties of PB molecules change, 
along with temperature, against time.45 This occurs through 
determining the temperature and heat flow (35°C–240°C) 
associated with PB transitions as a function of time.45 DSC 
spectra were analyzed for PB powder (Figure 6A), DCA 
powder (Figure 6B), SA powder (Figure 6C), PB-DCA-SA 
physical powder mixture (Figure 6D), PB-SA microcapsules 
(Figure 6E), and PB-DCA microcapsules (Figure 6F).
PB powder analysis (Figure 6A) showed a large 
peak at 128°C, which corresponds to the melting point 
of PB.45,46 DCA powder analysis (Figure 6B) showed a 
small peak at 178°C, which corresponds to the melting 
point of DCA.36 SA powder (Figure 6C) showed a large 
peak at 200°C, which corresponds to the melting point of 
SA.47 PB-DCA-SA physical powder mixture (Figure 6D) 
showed only two distinct peaks, one peak at 130°C, which 
corresponds to PB, and one at 200°C, which corresponds 
to SA. The slight shift to the right in both peaks suggests 
an increase in the melting point of the combined mixture, 
which reflects findings from the authors’ previous work.48 
PB-DCA-SA powder analysis only showed two peaks, PB 
and SA, while the peak that corresponds to DCA was miss-
ing, possibly due to a shift in the thermal capacity within the 
35°C–240°C range or due to an overlap between DCA and 
SA peaks.45 The PB-SA microcapsule (Figure 6E) showed 
two peaks – a small peak at 128°C, which corresponds to 
the melting point of PB, and a large peak at 202°C, which 
corresponds to the melting point of SA – with a slight 
shift to the right possibly due to ionic interaction between 
PB and SA post-microencapsulation. The PB-DCA-SA 
microcapsule (Figure 6F) showed two peaks, similar to 
the PB-DCA-SA powder mixture (Figure 6D). Overall, 
DSC analysis showed a transparent and interference-free 
integration of two prominent peaks – one corresponding 
to PB and the other to SA, with the possibility of overlap 
between DCA and SA. There was a noticeable slight shift 
pre- and post-microencapsulation, which could represent 
potential chemical interactions between SA and DCA in 
the microcapsule matrix, alterations in the crystallinity, 
polymorphism, and plasticization of SA, or a possible com-
bination of factors leading to an endothermic shift.49 Most 
importantly, PB did not seem to significantly participate in 
a crosslinking reaction, and retained its chemical integrity 
during the microencapsulation process, which is also sup-
ported by the FTIR results (Figure 7).45,46
Table 1 Viscosities and related parameters of both microencapsulated formulations
Formula code Set speed rpm Viscosity (mPa⋅s) Shear rate (s-1) Torque (mNm) Shear stress (Pa) 
PB-sa 1 20 UD 23.9±1 UD UD
2 35 UD 42.2±2 UD UD
3 61 UD 74.5±2 0.08±0.02 UD
4 107 25±0.2 125.1±2 0.11±0.01 3.2±0.01
5 187 20±0.1 222.2±3 0.17±0.03 4.5±0.01
6 327 15±0.1 385.7±4 0.21±0.01 5.7±0.03
7 572 10±0.3 681.8±8 0.26±0.03 6.9±0.02
8 1,000 9±0.1 1,194±10 0.40±0.01 10.9±0.01
PB-Dca-sa 1 20 UD 28±1 UD UD
2 35 UD 42.1±2 UD UD
3 61 UD 74.4±3 UD UD
4 107 UD 124.9±5 UD UD
5 187 UD 221.9±7 0.11±0.01 UD
6 327 12±0.2 385.0±5 0.16±0.03 4.5±0.03
7 572 11±0.1 681±10 0.27±0.02 7.2±0.01
8 1,000 10±0.2 1,195±12 0.43±0.01 11.7±0.02
Note: n=3. Data are described as mean ± sD.
Abbreviations: Dca, deoxycholic acid; PB, probucol; sa, sodium alginate; sD, standard deviation; UD, undetected (below the instrument limit of detection).






The FTIR method is widely used to stimulate vibrational lev-
els of known chemical groups in a molecule, and was used to 
confirm the chemical compatibility of PB with the SA polymer 
and DCA in the microencapsulation formulation.45 In line with 
the DSC analysis (Figure 5), FTIR spectra were analyzed for 
PB powder (Figure 7A), DCA powder (Figure 7B), SA pow-
der (Figure 7C), PB-DCA-SA powder (Figure 7D), PB-SA 
microcapsules (Figure 7E), and PB-DCA-SA microcapsules 
(Figure 7F). FTIR spectral analysis of individual powders, 
mixed powders containing all the ingredients, and final 
microcapsules attained was necessary to ensure the chemical 
compatibility of PB pre- and post-microencapsulation.
FTIR PB powder analysis (Figure 7A) showed char-
acteristic peaks at 2,959, 1,422, and 1,310 cm-1. DCA and 
SA individual powder analysis (Figures 7B and C) showed 
similar characteristics to the authors’ published work.27 
The PB-DCA-SA physical powder mixture (Figure 7D) showed 
peaks that correspond to PB, DCA, and SA with no interfer-
ence, dilution, or alterations. This confirms compatibility of 
all the ingredients in the powder form pre-microencapsulation. 
PB-SA microcapsule analysis (Figure 7E) showed five distinct 
and interference-free peaks, which correspond to PB and SA 
analysis, at 3,350, 1,422, 1,309, 1,602, and 1,025 cm-1. Similar 
peaks were noticed after DCA addition, which is in line with 
the DSC findings (Figure 6), suggesting an interaction between 
DCA and SA. PB-DCA-SA microcapsule analysis (Figure 7F) 
showed three PB peaks (at 3,350, 1,426, and 1,309 cm-1) and 
two SA peaks (at 1,601 and 1,025 cm-1), which is in line with 
the DSC analysis (Figure 6F).
Overall, FTIR analysis showed compatibility of the for-
mulation pre- and post-microencapsulation. The absence of 
DCA peaks is in line with the DSC analysis (Figure 6) and 








































40 60 80 100 120 140 160 180 200 220 240







































































Figure 6 Differential scanning calorimetric thermograms of the individual powders, mixed powder containing all the ingredients, and microcapsules.
Notes: (A) PB powder. (B) Dca powder. (C) sa powder. (D) PB-Dca-sa powder. (E) PB-sa microcapsules. (F) PB-Dca-sa microcapsules.
Abbreviations: Dca, deoxycholic acid; PB, probucol; sa, sodium alginate.
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interaction between DCA and the polymer SA. However, this 
interaction did not interfere with PB peaks as shown by the 
chemical (FTIR) and thermal (DSC) analyses. This suggests 
PB stability pre- and post-microencapsulation, as its chemical 
composition and structural integrity were maintained when 
microencapsulated with DCA.
This is a comprehensive study with in-depth in vitro 
analysis of novel bile acid–PB microcapsules with good 
potential in the treatment of T2D. A major limitation, and 
thus future work, is in vivo analysis carried out by adminis-
tering these microcapsules to an animal model of T2D and 
elucidating efficacy and safety profiles.
Conclusion
PB-DCA-SA microcapsules showed good morphology and 
stability and may be suitable for optimized oral delivery of 
PB in T2D. A future study may investigate the release kinet-
ics and pH-targeted delivery of the microcapsules at various 
pH and temperature values.
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